{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:03:09Z","timestamp":1788447789728,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["WBS4708719"],"award-info":[{"award-number":["WBS4708719"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["TYH2020302"],"award-info":[{"award-number":["TYH2020302"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.modpat.2026.100978","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:04:33Z","timestamp":1771315473000},"page":"100978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Estrogen Receptor, GATA-3, TTF-1, and KRAS in Endometrial Carcinoma of No Specific Molecular Profile: Prognostic or Diagnostic Markers?"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2163-0230","authenticated-orcid":false,"given":"Emma","family":"Siili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Loukovaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"B\u00fctzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annukka","family":"Pasanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.modpat.2026.100978_bib1","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer - combined analysis of PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.modpat.2026.100978_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"issue":"27","key":"10.1016\/j.modpat.2026.100978_bib3","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1200\/JCO.23.00062","article-title":"Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial cancer","volume":"41","author":"Horeweg","year":"2023","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.modpat.2026.100978_bib4","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100978_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.modpat.2026.100978_bib6","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO\u2013ESTRO\u2013ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2026.100978_bib7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/PAS.0000000000001873","article-title":"Mesonephric-like endometrial carcinoma: results from immunohistochemical screening of 300 endometrial carcinomas and carcinosarcomas for this often overlooked and potentially aggressive entity","volume":"46","author":"Mills","year":"2022","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.100978_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/PAS.0000000000001193","article-title":"A combined morphologic and molecular approach to retrospectively identify KRAS-mutated mesonephric-like adenocarcinomas of the endometrium","volume":"43","author":"Kolin","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.modpat.2026.100978_bib9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/his.15393","article-title":"Papillary and ductal patterns of mesonephric-like adenocarcinomas are often overlooked: a retrospective revaluation of over 1000 endometrial carcinomas","volume":"86","author":"Akbari","year":"2025","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2026.100978_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2024.10.028","article-title":"Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer","volume":"192","author":"Vrede","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.modpat.2026.100978_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2024.06.016","article-title":"The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup","volume":"189","author":"Aro","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.100978_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2026.100978_bib13","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2026.100978_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cjp2.82","article-title":"Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification","volume":"3","author":"Karnezis","year":"2017","journal-title":"J Pathol Clin Res"},{"issue":"3","key":"10.1016\/j.modpat.2026.100978_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/IGC.0000000000001187","article-title":"Added value of estrogen receptor, progesterone receptor, and L1 cell adhesion molecule expression to histology-based endometrial carcinoma recurrence prediction models: an ENITEC collaboration study","volume":"28","author":"van der Putten","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.modpat.2026.100978_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.humpath.2020.12.003","article-title":"The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study","volume":"109","author":"van Weelden","year":"2021","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.100978_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"issue":"7","key":"10.1016\/j.modpat.2026.100978_bib18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41379-020-0501-8","article-title":"Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma","volume":"33","author":"Pasanen","year":"2020","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.100978_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/PAS.0000000000001395","article-title":"PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups","volume":"44","author":"Pasanen","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.modpat.2026.100978_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253472","article-title":"Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma","volume":"16","author":"Pasanen","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.modpat.2026.100978_bib21","series-title":"WHO Classification of Tumours Series","first-page":"4","article-title":"Female Genital Tumours","year":"2020"},{"issue":"4","key":"10.1016\/j.modpat.2026.100978_bib22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/his.15241","article-title":"The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile","volume":"85","author":"Alafraidi","year":"2024","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.modpat.2026.100978_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/PGP.0000000000000490","article-title":"Comparison of different scoring systems in the assessment of estrogen receptor status for predicting prognosis in endometrial cancer","volume":"38","author":"Wang","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100978_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PGP.0000000000001112","article-title":"Clinicopathological and molecular characterization of high grade endometrial carcinomas of no specific molecular profile (NSMP) stratified by ER status","volume":"45","author":"Timmermans","year":"2026","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2026.100978_bib25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/PAS.0000000000001612","article-title":"Clinicopathologic characteristics of mesonephric adenocarcinomas and mesonephric-like adenocarcinomas in the gynecologic tract: a multi-institutional study","volume":"45","author":"Pors","year":"2021","journal-title":"Am J Surg Pathol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:34:01Z","timestamp":1782128041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0893395226000219"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.100978","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estrogen Receptor, GATA-3, TTF-1, and KRAS in Endometrial Carcinoma of No Specific Molecular Profile: Prognostic or Diagnostic Markers?","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.100978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100978"}}